EDMOND: A FEASIBILITY STUDY OF ELEMENTAL DIET AS AN ALTERNATIVE TO PARENTERAL NUTRITION FOR OVARIAN CANCER PATIENTS WITH INOPERABLE MALIGNANT BOWEL OBSTRUCTION

1Agnieszka Michael, 2Lindsey Allan, 3Kate Bennett-Eastely, 4Rebecca Herbertson, 5Simon Skene. 1University of Surrey; School of Biosciences and Medicine, 2Royal Surrey Foundation Trust; Oncology, 3University of Surrey; Clinical Trials Unit; 4Brighton and Sussex Hospital; Oncology, 5University of Surrey; School of Medicine

Methodology The primary objective of the study was to establish if ED can be used as an alternative to home PN in patients with IBO. The secondary aim was to examine the impact of ED on quality of life. The primary endpoints of the study were acceptability and tolerability of ED with respect to taste, and incidence of vomiting and pain. The secondary endpoints included the number of patients alive at the end of the study, quality of life, nutritional intake, and the number of women who can tolerate ED and subsequently be treated with palliative chemotherapy (as per standard of care).

Results 29 women with IBO caused by metastatic ovarian cancer were recruited into the EDMOND study. Of those 8 could not complete the trial due to disease progression, and 2 had missing data that was deemed irretrievable, leaving 19 patients who contributed data to the primary endpoint analysis. The mean age of the patients who continued the trial was 68 (SD 12.5). Preliminary analysis shows that 68.4% of patients met the primary endpoint and tolerated ED; the ED did not worsen the vomiting or pain as measured by Memorial Symptoms Assessment Scale. At baseline 72% of patients experienced vomiting and this number reduced to 28% by the end of week 1 and 23.5% by the end of week 2. 96% of patients reported pain at baseline and this proportion reduced to 72% and 76% by the end of week 1 and 2 respectively.

Conclusion ED is well tolerated by patients with IBO and can provide an acceptable feeding option for this group of patients.

Disclosures Authors have no conflict of interest.

ORAL METRONOMIC CYCLOPHOSPHAMIDE IN RECURRENT OVARIAN CANCER: A SINGLE CENTRE EXPERIENCE

1Daniela Attianese, 1Emico Badellino, 1Michela Villa, 2Marco Bellero, 3Roberta Massobrio, 4Nicoletta Biglia, 1Annamaria Ferero, 1Maurizio Hospital; Academic Department Gynaecology, 1Maurizio Hospital; Hospital Pharmacy

Methodology We selected patients treated with OMC (50 mg daily) from 2016 to 2020 at the Academic Department Gynaecology, Maurizio Hospital, Torino, Italy. Progression free survival (PFS) and toxicities profile were evaluated.

Results Thirty-five patients were analyzed. 28 (87%) had FIGO stage III and IV disease at diagnosis and 59% had received ≥ 4 previous lines. Average age was 68 years (range 47–88). Before starting OMC 16% had ECOG 0, 65% ECOG 1 and 19% ECOG 2. Median PFS was 5 months. PFS was ≥ 6 months in 33% of patients, ≥ 12 months in 13% and ≥ 18 months in 7%. 52% experienced clinical benefit in terms of symptoms reduction. 3% of discontinuation for side effects and no G3–4 hematological toxicities reflected a low toxicity profile. Only nausea and fatigue G1-G2 were reported in 4 (12%) and 9 (28%) cases, respectively.

Conclusion OMC could be a feasible alternative therapy for recurrent ovarian cancer leading to an acceptable clinical response with a low toxicity profile, even if patients are heavily pretreated and with a suboptimal performance status.

Disclosures Authors have no conflict of interest.

NIRAPARIB OUTCOMES IN BRCA WILD-TYPE PLATINUM SENSITIVE RECURRENT OVARIAN CANCER: A COMPARISON OF REAL-WORLD DATA TO THE NOVA TRIAL

Douglas Cartwright, Patricia Roxburgh, Barbara Stanley, Jennifer Brown, Alistair McLaren, Sarah Coulter, Carla Forte, Ross Glasspool, Beatson West of Scotland Cancer Centre

Methodology Data was collected retrospectively for all women receiving maintenance niraparib for BRCA wild-type, platinum sensitive recurrent ovarian cancer. The eligibility criteria set out in niraparib licence are less stringent than those in the NOVA trial, therefore outcomes may be different in the real-world to those observed in trial patients. The optimal management of patients after progression on PARPi is unknown and the relationship between platinum free interval and probability of response to platinum may be modified after PARPi therapy. To investigate this, we performed a retrospective analysis of real-world niraparib use and compared it to the NOVA trial.